Format

Send to

Choose Destination
See comment in PubMed Commons below
Hematol Oncol Clin North Am. 2013 Aug;27(4):657-72, vii. doi: 10.1016/j.hoc.2013.05.009.

Breast cancer prevention by antihormones and other drugs: where do we stand?

Author information

1
Division of Cancer Prevention and Genetics, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy.

Abstract

Breast cancer is the most common cancer in women worldwide. The selective estrogen-receptor (ER) modulators tamoxifen and raloxifene are approved by the Food and Drug Administration for the preventive therapy of breast cancer. Other drugs have shown promise but need further assessment. In the present review, we present an update of the chemoprevention of ER-positive breast cancer and discuss the potential role of metformin and aspirin, 2 drugs other than the specific "antihormones."

KEYWORDS:

Aromatase Inhibitors; Aspirin; Breast cancer chemoprevention; Metformin; Selective estrogen receptor modulators

PMID:
23915737
DOI:
10.1016/j.hoc.2013.05.009
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center